New leadership at European PCI association
This article was originally published in Clinica
Professor Carlo Di Mario has been elected president of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), part of the European Society of Cardiology (ESC), at the end of this month. He formally replaces William Wijns on August 31, during the two-year-old association's general assembly. EAPCI, in collaboration with European medtech industry association Eucomed, recently launched the "Stent for Life" initiative. Its mission is to "improve the delivery and patient access to the life saving indications of percutaneous cardiovascular interventions, thereby reducing the mortality and morbidity of patients suffering from acute coronary syndromes".
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.